Healthcare Featured

The World's Most Expensive Medicines Can't Find Their Patients

Million-dollar cures for sickle cell and inherited disease finally exist — but two years in, almost no one is getting them. The science is finished; the business model isn't. Here's who profits when it gets fixed.

Alpha One

20 Jun 2026 • 6 min read

For the first time in history, medicine can cure sickle cell disease with a single infusion. It can correct the genetic defect behind certain inherited blindness, halt a fatal childhood brain disease, and free hemophiliacs from a lifetime of injections. These are not incremental improvements. They are cures — the thing the pharmaceutical industry has promised for fifty years and almost never delivered.

And almost no one is getting them.

Two and a half years after the world's first CRISPR-based medicine was approved, the gap between what these therapies can do and how many patients actually receive them has become the defining problem of modern medicine. The science is finished. The business model is not. And how that gap gets closed will decide whether the gene therapy revolution becomes a trillion-dollar industry or a graveyard of brilliant drugs no one could figure out how to sell.

The miracle nobody is buying

Start with the numbers, because they are stark.

Casgevy, the Vertex–CRISPR Therapeutics treatment for sickle cell disease, carries a list price of roughly $2.2 million. Its direct competitor, bluebird bio's Lyfgenia, runs about $3.1 million. These are one-time treatments. Pay once, and a disease that previously meant a lifetime of pain crises, hospitalizations, and shortened life expectancy is, for many patients, simply gone.

By the end of 2025 — two full years after approval — just 64 patients worldwide had been infused with Casgevy. Sixty-four. For a disease that afflicts roughly 100,000 Americans and millions globally. Lyfgenia's uptake has been even slower; bluebird's own executives have warned that supply-chain constraints may keep them from reaching even 10% market penetration.

This is not a story about a drug that doesn't work. It is a story about a drug that works almost too well for the system that has to pay for it.

Why a cure is harder to sell than a pill

The pharmaceutical industry was built on chronic medication. You take a pill every day, for years, and the manufacturer collects revenue every month for the rest of your life. The entire financial architecture of healthcare — insurance pools, reimbursement codes, pharmacy benefit managers — is engineered around that recurring model.

A one-time cure breaks all of it.

Consider the math from an insurer's perspective. A $2 million infusion is an enormous upfront cost booked in a single year. But the savings — fewer hospitalizations, fewer transfusions, decades of avoided treatment — accrue slowly, over a lifetime. Worse, in America's fragmented insurance market, the patient who gets cured this year will likely have switched to a different insurer in three years. The company that paid for the cure never recoups the savings. It simply eats a seven-figure cost so that a competitor, or Medicare, enjoys the benefit down the road.

That misalignment is fatal to adoption. It is why the most transformative medicines ever invented have launched into a wall of prior authorizations, coverage disputes, and administrative delay. The treatment process itself is brutal — months of cell collection, chemotherapy to clear bone marrow, hospitalization for the infusion, and a long recovery. Few hospitals are equipped to deliver it. The patient pipeline clogs at every step.

The fix isn't a lower price. It's a new financial machine.

Here is the part the market is mispricing: the solution that's emerging isn't cheaper drugs. It's a wholesale re-engineering of how cures get paid for — and that machinery is being built right now.

The most important development is the CMS Cell and Gene Therapy Access Model, a federal program that lets the government negotiate outcomes-based contracts on behalf of state Medicaid programs. The structure is elegant: the manufacturer only collects full payment if the therapy actually works over time. If the patient relapses, the maker refunds part of the price. As of early 2026, 34 state Medicaid programs had signed on for the sickle cell therapies — a critical mass, given that Medicaid covers a disproportionate share of sickle cell patients.

This is the unlock. Outcomes-based payment solves the insurer's core fear — paying millions for a cure that might not last — by tying the check to results. Roughly 90% of eligible U.S. patients now have a reimbursement pathway, up from almost none at launch. And the effect is already visible: of those 64 Casgevy patients, nearly half were infused in the final quarter of 2025 alone. The curve is bending. Vertex is guiding to a steep revenue ramp in 2026 as the access machinery finally catches up to the science.

What it means for money

This is where the investor lens matters, because the market is treating gene therapy as a binary — miracle or money pit — when the real story is a transition.

The infrastructure layer may matter more than the drugs. The hardest part of gene therapy isn't discovery; it's manufacturing, cell processing, cold-chain logistics, and the specialized treatment centers that administer the therapies. The companies that own that infrastructure — contract manufacturers, viral-vector specialists, and the commercialization vendors who handle reimbursement plumbing — capture value regardless of which specific drug wins. In a gold rush, sell shovels.

Big pharma's retreat is a signal, not just a warning. Several large players that once called cell and gene therapy a portfolio cornerstone have quietly backed away as timelines, manufacturing burdens, and reimbursement complexity collided with easier bets. That retreat depresses sentiment across the sector — and creates the classic setup where the durable winners are the specialists who never had the option to walk away. Vertex, with a balance sheet built on its cystic fibrosis franchise, can afford to grind through a slow ramp that would bankrupt a single-asset biotech.

The payment model is the real platform. Whoever standardizes outcomes-based contracting for million-dollar cures builds the rails for an entire generation of therapies. The global cell and gene therapy market is projected to grow from roughly $45 billion in 2026 to nearly $150 billion by 2033 — but that forecast is meaningless without the financial architecture to pay for the products. The CMS model is the prototype. Watch whether it expands beyond sickle cell to the next wave of approvals, because that expansion is the on-ramp for the entire sector's revenue.

The bottom line

The gene therapy revolution didn't fail. It arrived years before the system designed to pay for it. The science raced ahead; the money is now catching up, and the mechanism doing the catching — outcomes-based payment, federally brokered — is the most underappreciated development in healthcare.

For patients, the slow rollout is a tragedy measured in lives. For investors, it's a roadmap. The cures are real. The companies that will profit aren't necessarily the ones with the best science — they're the ones positioned where the science meets the checkbook. That intersection, not the laboratory, is where the next decade of healthcare returns will be decided.

Get this level of intelligence every day. Subscribe to AlphaBriefing — free, member, and paid tiers available.

Sources & Further Reading

Disclaimer

AlphaBriefing is an independent intelligence publication. The content in this article is produced for informational and educational purposes only. Nothing published by AlphaBriefing constitutes financial, investment, legal, tax, or regulatory advice, nor should it be construed as a solicitation or recommendation to buy, sell, or hold any security, asset, or financial instrument.

All views expressed are those of the author at the time of writing and are subject to change without notice. Markets are volatile and unpredictable; past performance is not indicative of future results. Any investment involves risk, including the possible loss of principal.

AlphaBriefing and its principals, employees, or contributors may hold positions in securities or assets mentioned in this article. This should be considered a potential conflict of interest. No material relationship with any company referenced exists unless explicitly disclosed. Readers should conduct their own due diligence and consult qualified financial, legal, and tax advisors before making any investment decisions.

Information in this article is drawn from public sources believed to be reliable at the time of publication. AlphaBriefing makes no warranty, express or implied, as to the accuracy, completeness, or timeliness of any information herein. AlphaBriefing accepts no liability for any loss or damage arising from reliance on this content.